QFW
ALNY icon

QTR Family Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

QTR Family Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-609
Closed -$278K – 278
2025
Q3 		$278K Buy
+609
New +$248K 0.13% 179

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

QTR Family Wealth's ALNY Position: Q4 2025 in Review

QTR Family Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 609 shares — an estimated $278K sold.

QTR Family Wealth first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $278K in Q3 2025. 850 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • QTR Family Wealth reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • QTR Family Wealth sold 609 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $278K.
  • QTR Family Wealth first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • QTR Family Wealth's Alnylam Pharmaceuticals position peaked at $278K in Q3 2025.
  • 850 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on QTR Family Wealth's 13F filing for Q4 2025, filed 13 Feb 2026.